• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
26
Aug
2016

EpiPen Pricing Fury, Pfizer’s $14B Megabid for Medivation & Denali Grabs $130M

/
Luke Timmerman
/
1
/
All, Strategy
26 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Aug
2016

Illumina Takeout? Ha!, Portola Stumbles, and NYT Biotech Ace Moves On

/
Luke Timmerman
/
0
/
All
19 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
15
Aug
2016

Watching the Watchdog: How Does ICER Determine ‘Fair’ Prices for Drugs?

/
Leora Schiff
/
1
/
All, Drugs, Payers
15 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
Aug
2016

Zika Advances, Biogen’s Hemophilia Spinout, & Postdocs Get a Raise

/
Luke Timmerman
/
0
/
All
12 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Aug
2016

BMS Loss is Merck’s Gain, Biogen Takeover Speculation, & GSK’s Bioelectronics Foray

/
Luke Timmerman
/
0
/
All
05 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Aug
2016

Donating Your Personal Data: Giving Pay-to-Play a Whole New Meaning

/
Lisa Suennen
/
0
/
All, Genomics
03 Aug 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
29
Jul
2016

An Alzheimer’s Whiff, BioMarin’s Promise for Hemophilia, & a Seres Meltdown

/
Luke Timmerman
/
0
/
All
29 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Jul
2016

Scangos Exits, Relypsa Gets Bought, & Jounce Snags $261M From Celgene

/
Luke Timmerman
/
0
/
All
22 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
18
Jul
2016

Want to Help Biopharma’s Reputation Problem? Tackle Poverty

/
Kyle Serikawa
/
0
/
All, Politics
18 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Jul
2016

The Best Boring Companies in Biotech

/
Luke Timmerman
/
1
/
All
11 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
Jul
2016

Juno Deaths, Amgen Undercuts Humira, and Obama’s 1M Citizen-Scientist Dream

/
Luke Timmerman
/
0
/
All
08 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Jul
2016

How Brexit Changed the Way I Look at Biopharma’s Reputation Problem

/
Kyle Serikawa
/
1
/
All, Politics
07 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Jul
2016

The Schultz Lab Alumni: See Where They Are Now

/
Luke Timmerman
/
1
/
All
05 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
Jul
2016

Impressions from the Moonshot, Gilead’s New HCV Drug, & Nobelists Rip Greenpeace

/
Luke Timmerman
/
2
/
All
01 Jul 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Jun
2016

Pfizer, GSK, AbbVie Join $51.5M Bet on Computational Drug Discovery Shop, Morphic Therapeutic

/
Luke Timmerman
/
1
/
All, Drugs, Venture Capital
30 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
27
Jun
2016

The VP is Asking for Advice on Cancer. Share Yours Before I Go To Washington

/
Luke Timmerman
/
2
/
All, Cancer, Politics
27 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Jun
2016

Obama Toys With Precision Med Job, Gates Shines Light on Superbugs, & Parker Angles Into CRISPR Trial

/
Luke Timmerman
/
0
/
All
24 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Jun
2016

Going Public at Beaten Down Valuations? The Crossover Hangover

/
Luke Timmerman
/
0
/
All, Finance, Venture Capital
20 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Jun
2016

Opioid Kickbacks Exposed, Infinity Crashes & Merck’s PD-1 Extends Lives

/
Luke Timmerman
/
0
/
All
17 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Jun
2016

The Schreiberians: Where Are They Now?

/
Luke Timmerman
/
0
/
All, People
14 Jun 2016

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 67 68 69 70 71 … 79 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial
testimonial
testimonial

View More Testimonials ➛

Twitter

Tweets by ldtimmerman Follow @ldtimmerman
© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder